findmyKOL

Jia Yin, MD, PhD

Basic profile

Massachusetts Eye and Ear Infirmary

ORCID↗NPI↗
✓ Full record
RegionBoston, MA · NortheastSpecialtyOphthalmologyFocusOphthalmology
Active KOLfindmyKOL type: NationalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding2020–2026Why? →

Jia Yin is an Ophthalmology physician affiliated with Massachusetts Eye and Ear Infirmary. OpenAlex indexes 152 publications with 3,303 citations (h-index 32).

Overview

Scholarship

indexed output and impact (OpenAlex)
152publications

Distinct works indexed by OpenAlex, matched via ORCID.

3,303citations

Total citations across indexed works.

32h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
4NIH grants · 2020–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

243 Charles St
Boston, MA 021143002

Telephone

617-523-7900

Registry record last updated 13 Mar 2019.

View the NPPES registry record

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    53.7%
    Corticosteroid31.4%
    Prednisolone Acetate79%Fluorometholone22%
    Part D≥89 patients
    Corticosteroids, plain5.4%
    Loteprednol Etabonate65%Lotemax35%
    Part D<11 patients

    + 7 more classes in this area

  • Anti-infectives

    32.4%
    Fluoroquinolone Antibacterial20.2%
    Moxifloxacin100%
    Part D≥71 patients
    Macrolide5.7%
    Erythromycin100%
    Part D≥19 patients

    + 2 more classes in this area

  • Cancer & immunology

    3.9%
    Calcineurin inhibitor3.9%
    Cyclosporine100%
    Part D<11 patients
Where care is delivered (Part B)40.6% facility · 59.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

4 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”